Evading programmed cell death is a major hallmark of cancer cells and contributes to tumour progression and therapy resistance. Emerging hallmarks such as metabolic plasticity, genomic instability and an immunosuppressive tumour environment allow the tumours to escape from standard cytotoxic as well as targeted therapies. Thus, understanding the underlying mechanisms in appropriate pre-clinical/clinical models is crucial for the design of more effective combination therapies to avoid treatment failure or tumour recurrence.
Building on the strong success of four previous editions, this will be the 5th conference on this topic. Its objective is to cover recent and exciting developments in the field of cancer research that are crucial to our understanding of the multifaceted role of cell death in tumour initiation, progression and therapy response.